Literature DB >> 15963884

Progress in vaccines for sexually transmitted diseases.

Lawrence R Stanberry1, Susan L Rosenthal.   

Abstract

The development pipeline for vaccines to control sexually transmitted infections holds greater promise than ever before. Preclinical studies are encouraging in the development of chlamydia and gonococcal vaccines, and for the first time, recent clinical trials have shown the feasibility of creating vaccines to control genital herpes and cervical human papillomavirus infections. Behavioral research suggests that these vaccines will likely find acceptance among health care providers and consumers.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15963884     DOI： 10.1016/j.idc.2005.03.007

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


  8 in total

1.  Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Caixia Shen; Peter Andersen; Robert C Brunham
Journal:  Infect Immun       Date:  2012-01-30       Impact factor: 3.441

2.  Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.

Authors:  Hong Yu; Xiaozhou Jiang; Caixia Shen; Karuna P Karunakaran; Janina Jiang; Nicole L Rosin; Robert C Brunham
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

3.  Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.

Authors:  Tansi Khodai; Debbie Chappell; Clare Christy; Paul Cockle; Jim Eyles; Daisy Hammond; Katrina Gore; Michael J McCluskie; Dana M Evans; Susanne Lang; Peter T Loudon; Tim Townend; Paul Wright; Kate West; Helen Bright
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

4.  Manganese regulation of virulence factors and oxidative stress resistance in Neisseria gonorrhoeae.

Authors:  Hsing-Ju Wu; Kate L Seib; Yogitha N Srikhanta; Jennifer Edwards; Stephen P Kidd; Tina L Maguire; Amanda Hamilton; Kuan-Tin Pan; He-Hsuan Hsiao; Chen-Wen Yao; Sean M Grimmond; Michael A Apicella; Alastair G McEwan; Andrew H-J Wang; Michael P Jennings
Journal:  J Proteomics       Date:  2009-12-11       Impact factor: 4.044

5.  Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Robert C Brunham
Journal:  Vaccine       Date:  2014-06-30       Impact factor: 3.641

6.  Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs.

Authors:  Debra C Quenelle; Deborah J Collins; Terri L Rice; Mark N Prichard; Dante J Marciani; Earl R Kern
Journal:  Antiviral Res       Date:  2008-06-23       Impact factor: 5.970

7.  Extragenital manifestations of Neisseria gonorrhoeae.

Authors:  Steven E Spencer; Margaret C Bash
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.725

8.  Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models.

Authors:  Hong Yu; Xiaozhou Jiang; Caixia Shen; Karuna P Karunakaran; Robert C Brunham
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.